Veradermics 12-Month Phase 2/3 Data Shows Oral Minoxidil Hair Growth
Veradermics shares climbed 2.3% on Monday after the biotech released 12-month data from a Phase 2/3 study of its oral extended-release minoxidil pill, VDPHL01, for male pattern hair loss. Extended-Release … Read More